XML 42 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Supplemental Financial Statements Information - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
[1]
Inventory [Line Items]      
Inventory $ 786,356   $ 776,669
Depreciation expense, net of amounts capitalized into inventory 11,700 $ 12,500  
Gain on sale of nonfinancial assets, net 108,000 $ 0  
Valoctocogene Roxaparvovec      
Inventory [Line Items]      
Inventory $ 11,300    
[1] (1)December 31, 2021 balances were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on February 25, 2022.